532 Treatment with PEG-interferon and ribavirin for chronic hepatitis C does not decrease neutrophil and monocyte activity
Alessia Giorgini(Università Cattolica del Sacro Cuore), Massimo Zuin(AOL (United States)), Mauro Podda(University of Cagliari), Ana Lleò(Humanitas University), Anna Maria Ongari(University of Milan), Pietro Invernizzi(Azienda Ospedaliera San Gerardo), Barbara Ferrari(University of Milan), Carlo Selmi(University of Milan), F. Capsoni(Luigi Sacco Hospital), Alberto Benetti(AOL (United States))
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
|Nature Genetics|2013|398
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|394